Anthony D Sung, MD

Associate Professor of Medicine
Member of the Duke Cancer Institute
Senior Fellow in the Duke Center for the Study of Aging and Human Development
Campus mail Box 3961 Med Ctr, Durham, NC 27710
Phone (919) 668-1000
Email address anthony.sung@duke.edu

I am dedicated to the treatment of hematologic malignancies through cellular therapies such as hematopoietic stem cell transplantation (HCT). My research focuses on strategies to reduce complications of HCT and ranges from preclinical studies using murine models of HCT to Phase 1 and Phase 2 clinical trials. Areas of interest include the role of the microbiota (the trillions of bacteria living in and on our bodies), nutrition, and exercise in modulating HCT outcomes such as graft-versus-host disease (GVHD) and infections. In addition to advancing new pharmacological and cellular immunotherapies in support of these goals, we also are developing mobile health technologies (mHealth) to monitor patients at home, both as part of our innovative home transplant program as well as to improve follow up care of all our patients when they return home after transplant.

In Their Words

Education and Training

  • Fellowship, Hematology Oncology, Duke University School of Medicine, 2011 - 2014
  • Residency, Osler Medical Housestaff Training Program, Johns Hopkins University School of Medicine, 2008 - 2011
  • M.D., Harvard University , 2008

Grants

Publications

Sung, Anthony D., Shekeab Jauhari, Sharareh Siamakpour-Reihani, Arati V. Rao, Janet Staats, Cliburn Chan, Everett Meyer, et al. “Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.” Am J Hematol 95, no. 6 (June 2020): 662–71. https://doi.org/10.1002/ajh.25781.

PMID
32162718
Full Text

Hussaini, Syed, Yi Ren, Meagan Lew, Lauren Bohannon, Jillian C. Thompson, Yousuf Zafar, and Anthony Derek Sung. “Stem cell transplant and financial toxicity: A single-center prospective cohort analysis.” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Maung, Ko, Nelson Jen An Chao, Kelly Corbet, Ashley Morris Engemann, Cristina Gasparetto, Mitchell Horwitz, Yubin Kang, et al. “CLO20-049: Retrospective Study of Safety and Toxicity Profile Comparison for Propylene Glycol-Free Melphalan (Evomela®) and Generic Melphalan.” In Journal of the National Comprehensive Cancer Network, 18:CLO20-049. Harborside Press, LLC, 2020. https://doi.org/10.6004/jnccn.2019.7412.

Full Text

Smith, Patrick J., Meagan Lew, Yen P. Lowder, Kristi Romero, Jill Thompson, Lauren Bohannen, Alyssa Pittman, et al. “Cognitive Impairment in Candidates for Allogeneic Hematopoietic Stem Cell Transplantation.” In Biology of Blood and Marrow Transplantation, 26:S241–S241. ELSEVIER SCIENCE INC, 2020.

Scholars@Duke

Ramalingam, Sendhilnathan, Sharareh Siamakpour-Reihani, Lauren Bohannon, Yi Ren, Alexander Sibley, Andrew Nixon, Jing Lyu, et al. “Phase II Trial of Pasireotide to Prevent GI Toxicity and Acute Gvhd in Allogeneic HSCT.” In Biology of Blood and Marrow Transplantation, 26:S48–49. ELSEVIER SCIENCE INC, 2020.

Scholars@Duke

Thompson, Jillian, Yi Ren, Kristi Romero, Meagan Lew, Amy Bush, Julia Messina, Sin-Ho Jung, et al. “Financial Incentives to Increase Stool Collection Rates for Microbiome Studies in Adult Bone Marrow Transplant Patients.” In Biology of Blood and Marrow Transplantation, 26:S371–S371. ELSEVIER SCIENCE INC, 2020.

Scholars@Duke

Mishra, Asmita, Jaime M. Preussler, Zeina Al-Mansour, Veronika Bachanova, Vijaya Raj Bhatt, Christopher Bredeson, Saurabh Chhabra, et al. “Transplant Physicians' Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) Tool.” In Biology of Blood and Marrow Transplantation, 26:S45–46. ELSEVIER SCIENCE INC, 2020.

Scholars@Duke

Saullo, Jennifer L., Yanhong Li, Julia A. Messina, Jillian Thompson, Tara Dalton, Vinay K. Giri, Shelby D. Reed, et al. “Cytomegalovirus in Allogeneic Hematopoietic Transplantation: Impact on Costs and Clinical Outcomes Using a Preemptive Strategy.” Biol Blood Marrow Transplant 26, no. 3 (March 2020): 568–80. https://doi.org/10.1016/j.bbmt.2019.11.005.

PMID
31712193
Full Text

Peled, Jonathan U., Antonio L. C. Gomes, Sean M. Devlin, Eric R. Littmann, Ying Taur, Anthony D. Sung, Daniela Weber, et al. “Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation.” N Engl J Med 382, no. 9 (February 27, 2020): 822–34. https://doi.org/10.1056/NEJMoa1900623.

PMID
32101664
Full Text

Dandoy, Christopher E., Soyoung Kim, Min Chen, Kwang Woo Ahn, Monica I. Ardura, Valerie Brown, Saurabh Chhabra, et al. “Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant.” Jama Netw Open 3, no. 1 (January 3, 2020): e1918668. https://doi.org/10.1001/jamanetworkopen.2019.18668.

PMID
31913492
Full Text

Pages